Articles On Opthea (ASX:OPT)

The winds of CEO change bloweth through the early commercial-stage end of the market Trial news from Neurizon and Blinklab Opthea’s latest setback brings perversely good news   The long-standing CEOs of two early commercial stage biotech...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Month and quarter end offered some relief bottom fishing in US markets as traders te...

A ginger group of Mayne Health shareholders argues Cosette’s $600 million offer isn’t the right prescription Artrya gets to the heart of the matter after FDA approval Zelira Therapeutics goes to the ATM for $1 million   US healthcare grou...

Highlights: Regal Partners Ltd, an alternative investment manager, experienced significant share price movements throughout the week. A substantial decline occurred following developments related to Opthea Limited, a company in w...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

ASX All Ords dividend stock Regal Partners Ltd (ASX: RPL) is having a wild ride this week. Shares in the All Ordinaries Index (ASX: XAO) listed alternative investment manager closed down 8.85% on Thursday at $2.37. That followed on a gain o...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

Welcome to this week’s HotCopper Wire, our market watch podcast! Each week, HotCopper’s senior markets reporter Jonathon Davidson and I take you through all the week’s biggest news headlines — and what they mean for Aussie investors....

Highlights S&P/ASX 200 (ASX:XJO) breaches 8,000 mark, buoyed by cooling inflation. Robust gains in energy and mining sectors as commodity prices rally. Tuas (ASX:TUA) faces a sharp decline despite reporting a profitable half-year....

Shares in ASX eye diseases biotech Opthea Limited (ASX: OPT) remain frozen following a devastating update for investors. Opthea ASX shares haven't traded in more than a week and remain suspended at 60 cents apiece.   The stock will...

Immutep Ltd (ASX:IMM) has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial – the final stage of clinical study before the company eventually takes final efficacy results to regulators. Listen to the HotCo...

Highlights ASX 200 ends the session nearly flat James Hardie plunges on AZEK acquisition news Eight out of eleven sectors finish lower The Australian share market closed virtually unchanged on Monday, as strength in the consumer d...

The ASX 200 pushed into the green on a choppy Monday Fears around Trump’s tariffs trade war somewhat quelled The index was propped up by discretionary and financials sectors, as well as a couple of big miners   After a slow start, the ASX...

Highlights: Opthea's clinical trial results provide insights into the challenges of drug development within the biotechnology sector. Errawarra Resources strengthens its position in the mining industry through key acquisitions....

It mightn’t be too surprising Opthea (ASX:OPT) applied for a voluntary suspension last week ahead of Monday’s Phase 3 trial results – they throw the future of the company into question. Listen to the HotCopper podcast for in-depth discus...

The ASX has been trading flat at around 7,928 points. Discretionary has been the best performing sector today, up 1%, followed by Financials, up 0.66%, and Utilities, up 0.5%. Staples has been the worst performing, down 1%, followed b...

Highlights ASX dips slightly as global trade uncertainty looms (JHX) falls over 13% after announcing merger with AZEK (CBA) gains 1.1%, standing out in an otherwise cautious session The Australian sharemarket began the week on a c...

Highlights: The financial sector leads market gains, while utilities register the biggest decline. Opthea enters voluntary suspension ahead of COAST trial results release. Imugene secures FDA Fast Track Designation for its C...

The ASX has been trading flat at around 7,864 points. Financials has been the best performing sector, up 0.3%, followed by Materials, up 0.15% and Energy, up 0.1%. Utilities has been the worst performer, down 1.1%, followed by Industr...

Emvision to launch remote stroke detection trial It’s a tricky market but biotechs are raising funds Imugene wins FDA fast-track status for cancer program   Ahead of a wider trial, Emvision Medical Devices (ASX:EMV) has taken to the air w...

Week 12’s global rally is holding firm early this Tuesday morning, with ASX 200 futures pointing to a +0.83% gain (to 7,907 points) when trade begins at 10am in Sydney. Listen to the HotCopper podcast for in-depth discussions and insight...

The ASX has been up 0.62% at 7,837 points, following Wall Street’s Friday lead. It’s a sea of green today and Materials has been the best performing sector, up 1.55%, followed by Energy, up 1%, and Real Estate, up 0.66%. Health Care i...

Opthea shares enter trading halt on St Patrick’s Day ahead of a “material” trial update Imricor is on the hunt for funds, reportedly up to $80 million Race Oncology is in pole position for phase I trial start In the diabolically difficult...

Highlights: Opthea initiates a trading halt ahead of phase III clinical trial updates. Imricor Medical Systems advances funding efforts for US market entry. Race Oncology secures ethics approval for phase I trial of anti-can...

Highlights: The ASX200 experienced a decline, with the technology sector seeing the most significant impact. Companies such as Dropsuite, Nuix, and Opthea continue to demonstrate advancements in research and development. Str...

Highlights: The energy sector has shown growth, while telecommunications has experienced a downturn. Companies such as Larvotto Resources and Spartan Metals have recorded gains. Declines have been observed in Johns Lyng Group, Opthea...

Good afternoon and welcome to HotCopper’s Market Close, I’m Jonathon Davidson. The ASX remains below the 8,000pts mark as uncertainty on Wall Street tanks sentiment down under. Energy was the best performing sector up 1.5% while telec...

ASX health stocks fell 0.43% over the past week, while the broader market 2.51% ProMedicus has signed a seven-year, $40 million deal with leading US radiology provider LucidHealth Opthea falls following release of half-year results as it a...

Good Afternoon and welcome to HotCopper’s Market Close, I’m Jonathon Davidson. The ASX200 receded further just below the 8,100pts mark as the XJO continues to digest ongoing tariff implications. The US has flagged a 30 day pause for some...

ASX dips as traders weigh China’s stimulus against Trump’s tariffs Miners soften blow but insurance stocks still taking hits Trump gives speech to Congress, here’s what he said…   The ASX had a bit of a ride on Wednesday, with a sharp dip...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Like London buses, takeovers tend to come in a rush Mayne Pharma had struggled for years, but its performance was improving Takeovers in the ASX biotech sector have been few and far between The ‘London’ Bus theory goes that if one takeove...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Broker Rating Changes (Post Thursday Last Week) Upgrade CHARTER HALL RETAIL REIT ((C...

 Opthea completes patient visits for the first of two phase III eye disease trials Syntara’s secondary burns scar program shows promise Biome is in the black   The first of Opthea’s (ASX:OPT) two phase III eye disease trials has hit a k...

ASX small-cap shares are slightly outperforming in 2025, with the S&P/ASX Small Ordinaries Index (ASX: XSO) up 3.88% while the S&P/ASX 200 Index (ASX: XJO) is up 3.71% in the year-to-date. Many analysts have suggested this shoul...

Highlights • The ASX200 dipped slightly amid U.S. tariff concerns.• Australian tech firms demonstrate resilience and strong revenue growth.• Top performers include Dropsuite Limited (ASX:DSE), Nuix Limited (ASX:NXL), and Opthea Limited (...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Not as bad as feared. That seems to be the general mood as import tariffs against Me...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Trump and Mexico have come to a short-term agreement, with announced tariffs delayed...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Trump’s import tariffs on Mexico, Canada and China are triggering a flight for safet...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Canaccord rates Opthea a buy with target of $1.25 – $3 if Phase III trial is successful Opthea’s lead drug shows strong promise in eye disease trials Positive phase III results could lead to big gains for Opthea   Canaccord Genuity has in...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin SPI futures are suggesting Australia is not ready to join in on the global risk off...

ASX health stocks up 0.6% over past week, while the broader market rises 1%  EBR Systems is up ~58% in a month, briefly hitting Morgans price target of $1.76 Morgans drops rating of Nanosonics to a hold despite strong H1 FY25 Healthcare a...

Investors with a high tolerance for risk might want to take a look at the speculative ASX stock in this article. After all, the team at Bell Potter believes that it could deliver big returns for investors over the next 12 months if everythi...

Macquarie Group Ltd (ASX: MQG) shares are marching higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) diversified financial stock closed yesterday trading for $225.28. In morning trade on Wednesday, shares are changing hands f...

The ASX200 pared early gains and closed up 0.48% at 8,231 points. A lift in the iron ore price has driven big miners higher; Fortescue was the biggest winner, up 2.7%, followed by BHP, up 1.4% and Rio Tinto, up 0.8%. The Materials sec...

Growth investors are spoilt for choice on the Australian share market. That's because the local market is home to a large number of high-quality ASX growth shares with bright long-term outlooks. But which of the many growth shares out there...

Australia's banking landscape is dominated by the big four, but other ASX bank shares brought strong results for investors last year. The record highs in 2024 from the big four have been well documented, led by Commonwealth Bank of Austr...